SPOTLIGHT -
EP. 1: EGFR & ALK/ROS1 Testing in Squamous NSCLC
EP. 2: PD-L1 Testing in Squamous NSCLC
EP. 3: Pembrolizumab in Newly Diagnosed Squamous NSCLC
EP. 4: Toxicities Associated with Anti-PD-1 Immunotherapy
EP. 5: Pseudoprogression on Immunotherapy in Squamous NSCLC
EP. 6: Promising Immunotherapy Trials in Squamous NSCLC
EP. 7: Chemotherapy for Newly Diagnosed Squamous NSCLC
EP. 8: Maintenance Therapy for Squamous NSCLC
EP. 9: Choosing Second-Line Therapy for Squamous NSCLC
EP. 10: Further Sequencing in Squamous NSCLC
EP. 11: EGFR-Targeted Therapy for Squamous NCSLC
EP. 12: Final Thoughts on Squamous NSCLC Research
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
